The presence and regulation of connective tissue growth factor in the human endometrium

J.A. Maybin, J. Barcroft, U. Thiruchelvam, N. Hirani, H.N. Jabbour, and H.O.D. Critchley*

MRC Centre for Reproductive Health, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
*Correspondence address. Tel: +131-242-6439/6858; Fax: +131-242-6441; E-mail: hilary.critchley@ed.ac.uk

Introduction

The human endometrium is an excellent physiological model of cyclical tissue injury and repair. If pregnancy does not occur, the corpus luteum regresses in the late secretory phase and progesterone levels decline. This withdrawal of progesterone triggers an inflammatory response in the endometrium, which culminates in the menstrual shedding of the functional endometrial layer (Critchley et al., 2001; King and Critchley, 2010). Subsequent repair is very efficient, occurring without scarring or loss of function. However, the precise mechanisms involved remain poorly understood. Observational studies have shown that endometrial repair begins on Day 2, during active bleeding, and full coverage of the lumen is usually achieved by Day 6 (Ludwig and Spornitz, 1991). In addition, the endometrium is shed in a piecemeal fashion at menstruation with simultaneous repair occurring in adjacent areas (Garry et al., 2009). These studies highlight that factors involved in the initiation of endometrial repair ‘post-menses’ must be present at the time of menses itself.

Connective tissue growth factor (CTGF) is a multifunctional growth factor that is expressed at high levels during wound repair and at sites of connective tissue formation (Igarashi et al., 1993). Its biological effects include chemotaxis, differentiation, extracellular matrix (ECM) production, angiogenesis, tumour growth, wound healing and fibrosis (Igarashi et al., 1993; Frazier et al., 1996; Oemar et al., 1997; Hishikawa et al., 2000; Shimo et al., 2001; Ivkovic et al., 2003). It is, therefore, an attractive candidate for endometrial repair. CTGF protein and mRNA have previously been detected in the human endometrium by immunohistochemistry and northern blot analysis, respectively (Uzumcu et al., 2000). CTGF was localized to epithelial and endothelial cells in proliferative and secretory phase biopsies. Whereas, in contrast, endometrial stromal cells were only stained after decidualization in the late secretory phase (Uzumcu et al., 2000). Unfortunately, no menstrual phase biopsies were included in this study, but the presence of CTGF in the normal cycling endometrium suggests that it may facilitate tissue repair and remodelling after menses.
Committee.

Premenstrual progesterone withdrawal increases levels of cyclo-oxygenase (COX) 2 enzyme in the endometrium (Critchley et al., 1999), which stimulates the synthesis of endometrial prostaglandins (PGs), including prostaglandin E2 (PGE2) and F2α (PGF2α). PGF2α is emerging as a potential key player in the initiation of expression of endometrial repair factors. PGs have been demonstrated to induce a host of endometrial angiogenic factors including vascular endothelial growth factor, adrenomedullin, fibroblast growth factor-2 and interleukin-8 (Keightley et al., 2010; Maybin et al., 2011a,b,c). Functionally, PGF2α has been shown to increase endometrial epithelial cell proliferation in culture (Milne and Jabbour, 2003) and is known to induce vasoconstriction of endometrial spiral arterioles (Baird et al., 1996). There is evidence that this vasoconstriction results in a transient, local hypoxic insult in the uppermost endometrial layer at menstruation (Critchley et al., 2006; Fan et al., 2008).

We hypothesized that CTGF is increased at the time of endometrial repair and regeneration and that this putative repair factor is regulated by PGs and hypoxia.

Materials and Methods

Human endometrial tissue collection

Endometrial biopsies (n = 41) were collected with a suction curette (Pipelle, Laboratorie CCD, Paris, France) from women (median age: 42 years, range: 22–50) attending gynaecological out-patient departments across National Health Service Lothian. All women reported regular menstrual cycles (21–35 days) and no exogenous hormone exposure for 3 months prior to biopsy. Women with large fibroids (>3 cm) or endometriosis were excluded. Tissue was divided and (i) placed in RNA later, RNA stabilization solution [Ambion (Europe) Ltd., Warrington, UK], (ii) fixed in phosphate-stabilization solution [Ambion (Europe) Ltd., Warrington, UK], (iii) placed in phosphate-buffered saline for 10 min followed by goat polyclonal CTGF antibody (Santa Cruz Biotechnology) at a 1 in 100 dilution overnight at 4°C. Donkey anti-mouse peroxidase secondary antibody (Abcam, Cambridge, MA, USA) was used as a protein block and the sections were incubated with mouse monoclonal CD68 (a pan-macrophage antigen) antibody (Dako, Cambridge, CA, USA) for 10 min. The sections were incubated with normal donkey serum for 10 min followed by goat polyclonal CTGF antibody (Santa Cruz Biotechnology) at a 1 in 100 dilution overnight at 4°C. Alexa 546 donkey anti-goat secondary antibody (Invitrogen, Paisley, UK) was applied for 1 h, followed by a 4’,6-diamidino-2-phenylindole stain (Sigma, Dorset, UK) for 10 min. Sections were then mounted with permaflour (Thermo Scientific, Waltham, MA, USA) and analysed with a Zeiss LSM710 confocal microscope system.

Semi-quantitative histosoring of endometrial CTGF expression

Localization and intensity of immunostaining was evaluated blindly by two independent observers using a semi-quantitative scoring system (Asmundstad et al., 1992). The intensity of staining was graded with a three-point scale (0 = no staining, 1 = mild staining and 2 = strong staining). This was applied to the glands and stromal cells (n = 41), as well as the surface epithelium where visualized (n = 36). The percentage of tissue in each intensity scale was recorded. A value was derived for each of the cellular compartments by using the sum of these percentages after multiplication by the intensity of staining.

| Table I | Human endometrial biopsies used in this study. |
|---------|-----------------------------------------------|
| Stage of cycle | Number of biopsies | Mean serum estradiol levels, pmol/l (range) | Mean serum progesterone, nmol/l (range) |
|----------------|---------------------|------------------------------------------|-------------------------------------|
| Menstrual      | 8                   | 192.25 (55–514)                          | 3.71* (1.24–10.59)                 |
| Proliferative  | 11                  | 441.18 (79–1105)                         | 2.81* (0.97–7.10)                  |
| Early secretory| 7                   | 497.50 (289–841)                         | 59.60 (23.2–112.9)                 |
| Mid-secretory  | 8                   | 638.00 (242–1949)                        | 64.30 (25.47–114.53)               |
| Late secretory | 7                   | 318.22 (59.09–819)                       | 8.22* (1.06–16.95)                 |

*Significantly different from early and mid-secretory levels, P < 0.05.
Culture of endometrial cells

Human Ishikawa endometrial adenocarcinoma cells (European collection of cell culture, Centre for Applied Microbiology, Wiltshire, UK) were stably transfected with the PGF2α receptor (FPS cells) or a PGE2 receptor (EP2S cells) as previously described (Sales et al., 2004). To determine the effect of PGE2/F2α receptor/EP2S cells and/or hypoxic conditions on CTGF expression, ~4 × 10^5 FPS or EP2S cells were seeded in 6-well plates in Dulbecco's modified eagle's medium F-12 supplemented with 10% fetal calf serum, 1% penicillin/streptomycin and 200 μg/ml G418. The following day, cells were incubated in serum-free culture medium containing 8.4 μM indomethacin (COX enzyme inhibitor) for at least 16 h. Cells were then treated with vehicle or 100 nM PGE2/F2α and placed in normoxia (21% O2, 5% CO2, 37°C) or a sealed hypoxic chamber (0.5% O2, 5% CO2, 37°C) for 2, 4, 6, 8 or 24 h.

Culture of endometrial tissue explants

Endometrial biopsies (proliferative n = 3, secretory n = 3) were divided into four explants of equal size and incubated on raised platforms in 24-well plates, just covered with serum-free RPMI 1640 medium and 8.4 μM indomethacin for 16 h. One explant from each biopsy was then treated with vehicle in normoxia, one with 100 nM PGE2/F2α in normoxia, one with 100 mM PGE2 in normoxia and one with vehicle in hypoxia for 24 h.

Quantitative RT–PCR

Expression of CTGF in endometrial tissue and cells was determined by quantitative RT–PCR (QRT–PCR, Taqman) analysis. Total RNA from cells and endometrial biopsies was extracted using the RNeasy Mini Kit (Qiagen Ltd, Sussex, UK) according to manufacturer's instructions. DNA contamination of samples was removed by DNA digestion during RNA purification. RNA samples were reverse transcribed using MgCl2 (5.5 mM), deoxynucleotide triphosphates (0.5 mM each), random hexamers (2.5 μM), ribonuclease inhibitor (0.4 U/μl) and multiscribe reverse transcriptase (1.25 U/μl; all from PE Biosystems, Warrington, UK). Total RNA of 200 ng was added. A tube with no reverse transcriptase and a further tube with water were included as controls. To measure cDNA levels, a reaction mix was prepared containing Taqman buffer (5.5 mM MgCl2, 200 μM dATP 200 μM dCTP, 200 μM dGTP and 400 μM deoxyuridine triphosphate), ribosomal 18S primers/probe (Applied Biosystems, Warrington, UK) and specific forward and reverse primers and probes: CTGF forward primer 5'-TGCACCGCACAAGATGTTT-3', reverse primer 5'-GGCCACGTCACACTGTTA-3', probe 5'-CTCCTCGCATCTTGGGTACGTT-3' was added for each PCR reaction. Negative controls (water instead of cDNA) were included in each run. PCR was carried out using an ABI Prism 7900 (Applied Biosystems). Samples were analysed in triplicate using Sequence Detector version 2.3 (PE Biosystems), using the comparative threshold method. Expression of target mRNA was normalized to RNA loading for each sample using the 18S ribosomal RNA as an internal standard. There was no significant change in 18S rRNA expression between normoxic and hypoxic conditions.

CTGF protein quantification

CTGF secreted protein concentrations were measured using a human CTGF ELISA development kit (PeproTech, London, UK) according to manufacturer’s instructions. Colour development was measured on an enzyme-linked immunosorbent assay plate reader at 405 nm. The minimum detectable concentration of CTGF was 63 pg/ml. There was no significant cross-reactivity for human bone morphogenetic protein-4, CTGF/L/WNT inducible signalling pathway (WISP)-2, cystine rich protein-61, insulin-like growth factor (IGF)-I, IGF-II, IGF-BP1, nephroblastoma overexpressed gene, transforming growth factor-β, WISP-1 or WISP-3.

Statistics

For endometrium from across the menstrual cycle, mRNA results were expressed as the quantity relative to a comparator sample of RNA from the liver. Significant differences in mRNA and protein were determined using Kruskal–Wallis non-parametric test with Dunn’s multiple comparison post-test (Prism, version 4.02, GraphPad Software, Inc., San Diego, CA, USA). For cell culture, mRNA results are expressed as fold increase, where relative expression of mRNA after treatment was divided by the relative expression after vehicle treatment. Data are presented as mean ± SEM and significant differences among raw data determined using one-way analysis of variance with Tukey’s multiple comparison test. A value of P < 0.05 was considered significant.

Results

Endometrial CTGF mRNA expression

Endometrial CTGF mRNA expression varied significantly across the menstrual cycle (P = 0.0032; Fig. 1). Maximal CTGF mRNA expression was present in endometrium from the menstrual phase, with levels significantly greater than those found during the early (P < 0.01), mid- (P < 0.05) and late (P < 0.05) secretory phases.

Endometrial CTGF protein localization

CTGF was immunolocalized to the cytoplasm of surface epithelial, glandular epithelial, stromal and vascular endothelial cells or
Connective tissue growth factor in human endometrium

The endometrium from the menstrual and proliferative phases (Fig. 2A–D). There was an obvious reduction in staining intensity during the secretory phase (Fig. 2E and F). Intense staining of occasional cells in the stromal compartment of proliferative endometrium was observed (Fig. 2H). These cells were usually found in close proximity to the endometrial vasculature. Semi-quantitative scoring of immunohistochemical staining revealed significantly greater staining of the glandular epithelial, surface epithelial and stromal cells in proliferative phase endometrium when compared with mid-secretory endometrium (P < 0.001, P < 0.001, P < 0.01 respectively; Fig. 3).

Stromal CTGF was immunolocalized to macrophage cells

Proliferative endometrial tissue was subjected to dual staining immunohistochemistry for CTGF and CD68 (a pan-macrophage antigen). This revealed that the occasional stromal cells that were positively stained for CTGF also expressed CD68 (Fig. 4). Glandular epithelial cells were positively stained for CTGF but did not reveal dual staining for CD68.

CTGF expression was regulated by PGs and hypoxia

A time course experiment in EP2S cells revealed a significant increase in CTGF mRNA expression on treatment with 100 nM PGE2 compared with vehicle at 4 and 8 h (P < 0.01) (Fig. 5A). Hypoxic conditions (0.5% O2) also significantly increased CTGF mRNA expression in EP2S cells at 2 h versus normoxic controls (P < 0.001; Fig. 5B). Interestingly, in prolonged hypoxic conditions this up-regulation did not take place. When cells were treated with both PGE2 and hypoxia for 2 h, there was a synergistic increase in CTGF mRNA expression that was significantly greater than that seen with either treatment alone (P < 0.05; Fig. 5C). As maximal CTGF mRNA expression occurred between 2 and 4 h, the amount of CTGF protein secreted into culture supernatants was assessed by ELISA at a 6 h time point. CTGF secreted protein was below the level of detection of the ELISA in vehicle-treated cells but was significantly increased when EP2S cells were co-treated with PGE2 and hypoxia (P < 0.05; Fig. 5D). As in EP2S cells, hypoxic conditions did not significantly increase CTGF mRNA expression at 6 h in FPS cells (Fig. 5E). Secreted protein levels in culture supernatants at 24 h demonstrated significant increases in CTGF protein over controls after treatment with PGE2 (P < 0.001) (Fig. 5F).

Treatment of endometrial explants from the proliferative phase showed a modest increase in CTGF mRNA expression when explants were placed in hypoxic conditions (P < 0.05; Fig. 5G). Explants from the secretory phase displayed a more marked increase in CTGF mRNA expression in hypoxic conditions (P < 0.001; Fig. 5H). No significant increase in CTGF mRNA was observed when explants were treated with PGs, regardless of cycle stage.

Discussion

These data demonstrate maximal expression of CTGF in the human endometrium during the menstrual and proliferative phases; a time consistent with endometrial repair and regeneration. In addition, CTGF protein is localized to glandular epithelial cells and macrophages in the stromal cell compartment. Furthermore, this paper describes significant increases in CTGF mRNA and secreted protein in endometrial cells treated with PGs and/or hypoxia. These data provide a potential mechanism for the up-regulation of CTGF during the time of endometrial repair associated with menstruation.

The location and timing of endometrial repair

The data presented herein were generated from examination of endometrial biopsies collected with an endometrial sampler. The majority of endometrium collected with this method is from the functional layer. As this layer is sloughed off during menses, it has hitherto been assumed that endometrial repair was governed by factors present in the basal layer. An important recent study of menstrual endometrium from the superficial layer has revealed an increase in expression of genes associated with ECM biosynthesis in stromal cells from this upper layer when compared with those from the basal layer (Gaide Chevronnay et al., 2009). This suggests that fragments of the functional layer of endometrium do make an active contribution to the endometrial repair process. Further, recent laser capture microdissection techniques have identified that both the stromal and epithelial cell compartments have an active role in this repair process (Gaide Chevronnay et al., 2010).

Hysteroscopic, histological and scanning electron microscopy studies have documented the time course of endometrial repair. The endometrium is shed in a piecemeal fashion and repair commences in delineated areas while shedding occurs simultaneously in adjacent areas (Garry et al., 2009). Therefore, examination of endometrial repair factors during the menstrual phase is essential when examining the process of repair in the context of menstruation.

CTGF and endometrial repair

CTGF is a member of the CCN family of growth regulators (Brigstock, 2002) and has a putative role in endometrial repair. Data herein demonstrate maximal CTGF mRNA expression in menstrual phase endometrium. CTGF protein showed intensely positive immunohistochemical staining during the proliferative phase, which was significantly elevated in glandular epithelial, surface epithelial and stromal cells when compared with the mid-secretory phase. This is the first description of CTGF mRNA expression and protein staining intensity in human endometrium from all stages of the menstrual cycle, including at menstruation. A previous study immunolocalized human endometrial CTGF to epithelial, stromal and endothelial cells but did not examine endometrium from the menstrual phase (Uzumcu et al., 2000). In contrast to findings described herein, Uzumcu et al (2000) found minimal staining of stromal cells in proliferative tissue and maintenance of epithelial staining throughout the secretory phase. These differences may be explained by varying antibody specificities or by the classification of endometrial tissue studied. We have carefully staged the tissues used in this study based on reported day of cycle, serum ovarian hormone levels on the day of biopsy and histological dating. Other members of the CCN family also show significant variation in human endometrial expression across the cycle. The pro-angiogenic factor cysteine rich protein 61 ( Cyr61) was found
to be significantly elevated during menses (Gashaw et al., 2008) and authors proposed it contributes to repair, growth and maturation of the endometrial vasculature after menstruation.

The mechanism by which CTGF exerts its effects remains undefined at a molecular level, therefore examination of receptor expression for this factor was not possible. CYR61 (a member of the CNN family) has been shown to bind to integrin αvβ3 to mediate cell adhesion and migration (Kireeva et al., 1998) and CTGF may elicit its biological effects in a similar manner. Alternatively, it has been proposed that the CCN family may not signal exclusively via cell surface receptors but rather are a component of the ECM, bridging the functional gap between structural and active molecules (Lau and Lam, 1999).

Figure 2 CTGF immunohistochemical staining in human endometrium from across the menstrual cycle: (A and B) menstrual phase endometrium, (C and D) proliferative phase endometrium, (E and F) mid-secretory phase endometrium, (G) negative control menstrual endometrium, incubated with the primary antibody pre-absorbed with blocking peptide and (H) intense staining of occasional cells (arrows) in the stromal cell compartment of proliferative endometrium. Scale bar = 50 μm. Arrows, endothelial cells; GE, glandular epithelial cells; St, stromal compartment.
Other components of the ECM are known to have a fundamental role in the repair process and have a similar endometrial pattern of expression to that of CTGF. Fibronectin (FN) is a large glycoprotein that interacts with specific integrins to enhance cell adhesion and migration during wound repair (Kim et al., 1992). Utilizing the ovariectomized rhesus macaque model, Cao et al. (2007) demonstrated a 50-fold increase in FN expression from the secretory to the menstrual phase alongside a 17-fold increase in its receptor, integrin-β1. Real-time PCR, in situ hybridization and immunohistochemistry confirmed these findings and localized the increase in FN expression to the uppermost endometrial glands and luminal epithelium. Significant increases in adhesive molecules, such as CTGF and FN, in the functional layer of the endometrium at this time implicate involvement in surface healing post-menstruation.

Interestingly, we observed intense CTGF immunostaining of occasional stromal cells during the proliferative phase. Dual staining immunohistochemistry identified these cells as macrophages. Macrophages have a fundamental role in the inflammatory response and are often found at sites of intense tissue remodelling. They have been detected in the endometrium throughout the menstrual cycle (Bonatz et al., 1992) with a significant influx during the late secretory phase (Kamat and Isaacson, 1987). The importance of endometrial leukocytes in post-menstrual repair has been demonstrated in the mouse model of menstruation. Neutrophil depletion using the antibody RB6-8C5 markedly delayed endometrial repair when examined 48 h after progesterone withdrawal versus control animals (Kaitu’u-Lino et al., 2007). The role of macrophages during endometrial repair is still to be fully defined but macrophage depletion in the mouse model of endometriosis suggests a crucial role in growth and vascularization (Bacci et al., 2009). Detection of CTGF within endometrial macrophages is thought to be of an endocytotic nature from the surrounding environment where it potentially acts as a chemoattractant to peripheral mononuclear cells (Cicha et al., 2005). CTGF may be involved in the influx of macrophages to the endometrium during the latter stages of the menstrual cycle. There is recent evidence suggesting communication between macrophages and stromal cells in the human endometrium (Eyster et al., 2010). Endometrial stromal cells co-cultured with macrophage cell supernatant demonstrated significantly increased expression of CTGF over those cultured with vehicle. Moreover, this response was found to be abrogated in the presence of estradiol and progesterone. Hence, endometrial macrophages may contribute to the significant increase in stromal cell expression of CTGF at the time of menstruation, when ovarian hormone levels are low.

**Hypoxia and the induction of repair**

Herein we have demonstrated a significant increase in CTGF mRNA after exposure of endometrial epithelial cells and endometrial tissue explants to hypoxic conditions. The timing of increased CTGF in response to hypoxia was different in endometrial cells and tissue explants, with cells demonstrating a rapid response and tissue maintaining increased CTGF expression at 24 h. This may reflect the heterogeneous cell population that constitutes endometrial tissue. Tissue explants allow maintenance of cell–cell communication in vitro, mimicking the in vivo scenario more accurately than single cell culture.

It is postulated that a period of transient hypoxia occurs in vivo in the uppermost endometrial zones as spiral arterioles constrict following progesterone withdrawal. An early study in the rhesus monkey (Markee, 1940) revealed intense endometrial vasoconstriction, tissue necrosis and menstruation following progesterone withdrawal. More recently, the use of pimonidazole (hydroxyprobe®), a marker of oxygen partial pressures <10 mmHg, in the mouse model identified the presence of hypoxia during simulated menstruation (Fan et al., 2007).
In contrast, negligible levels of pimonidazole were observed by Day 5 after progesterone withdrawal. Furthermore, markers of tissue hypoxia (CAIX and hypoxia inducible factor-1α) have been detected immunohistochemically in the human endometrium during menstruation, with a distinct reduction in staining of both markers after cycle Day 5 (Critchley et al., 2006; Punyadeera et al., 2006).

**Prostaglandins and the induction of repair**

We also demonstrate significant increases in CTGF mRNA and protein expression in endometrial cells after incubation with PGE₂ and PGF₂α. These results contrast with findings in rat fibroblast cells and human airway smooth muscle cells, where PGE₂ treatment decreased CTGF mRNA expression (Yu et al., 2002; Burgess et al., 2006); highlighting the cell and tissue-specific nature of CTGF induction. We have demonstrated a synergistic increase in CTGF mRNA expression in endometrial cells treated with PGE₂ and hypoxia simultaneously. Both PGE₂ and PGF₂α have previously been shown to increase endometrial epithelial cell CYR61 mRNA expression (Gashaw et al., 2008). Furthermore, a synergistic increase with both hypoxia and PGE₂ was also demonstrated for this other member of the CCN family. Of note, CTGF mRNA was not increased in response to PGE₂/PGF₂α in endometrial tissue explants examined herein. This may be explained by a lack of FP receptors (the PGF₂α receptor) in human endometrial stromal cells (Miline and Jabbour, 2003), which may mask any epithelial increase in CTGF mRNA in whole tissue explants. Alternatively, the response of endometrial tissue to PG exposure in vitro may occur at a different time point. Owing to the limitations of human tissue availability, time-course experiments could not be performed.

As hypoxic conditions and increased PG synthesis have been demonstrated in the premenstrual endometrium following progesterone withdrawal, these factors may have an important role in the induction of CTGF. Their independent and synergistic actions may provide a robust mechanism for the stimulation of endometrial repair. Transforming growth factor (TGF)-β is well established as a transcriptional regulator of CTGF in other cell types (Harlow et al., 2002; Higgins et al., 2004). The role of TGF-β and other inflammatory mediators in endometrial CTGF expression remains to be determined.

**Conclusions**

This paper describes maximal CTGF levels in the menstrual and proliferative endometrium; a time consistent with endometrial repair. We
Figure 5 The regulation of CTGF by hypoxia and prostaglandins. (A) CTGF mRNA expression in EP2S cells treated with vehicle or 100 nM PGE₂ for up to 48 h in normoxic conditions (n = 3). (B) CTGF mRNA expression in EP2S cells cultured in normoxic and hypoxic conditions for up to 48 h (n = 3). (C) CTGF mRNA expression in EP2S cells treated with 100 nM PGE₂ and/or hypoxia for 2 h (n = 3). (D) Secreted CTGF protein levels in EP2S cell culture supernatant at 6 h (n = 3). (E) CTGF mRNA expression in FPS cells treated with 100 nM PGE₂ and/or hypoxia for 6 h (n = 3). (F) Secreted CTGF protein levels in FPS cell culture supernatant at 24 h (n = 3). (G) CTGF mRNA in endometrial tissue explants from the proliferative phase treated with vehicle, 100 nM PGE₂, 100 nM PGF₂α or hypoxia (n = 3). (H) CTGF mRNA in endometrial tissue explants from the secretory phase treated with vehicle, PGF₂α, PGE₂ or hypoxia (n = 3). N, normoxia (21% O₂); H, hypoxia (0.5% O₂); V, ethanol vehicle; PG, prostaglandin (*P < 0.05, **P < 0.01, ***P < 0.001). Fold changes are relative to findings in vehicle-treated controls in normoxic conditions.
describe the induction of CTGF by PGE2, PGF2\alpha, and hypoxic conditions and suggest these factors have a role in the perimenstrual endometrium to up-regulate CTGF expression for endometrial repair. Further studies are required to determine if aberrations in perimenstrual PG production or vasoconstriction lead to decreased CTGF levels and delayed repair, resulting in the clinical complaint of heavy or prolonged menstrual bleeding.

**Acknowledgements**

We would like to acknowledge Catherine Murray and Sharon McFarson for their help with patient recruitment. Thanks also to Ronnie Grant for his help with figure preparation, Sheila Milne for providing secretarial support and Sarah McDonald for her excellent technical support.

**Authors’ roles**

J.A.M. contributed to conception and design, acquired data, analysed and interpreted data and drafted the article. J.B. and U.T. acquired data, performed analysis and provided critical revisions of the manuscript. N.H., H.N.J, and H.O.D.C. contributed to conception and design and provided critical revision of the intellectual content of the manuscript. All authors provided final approval of the version to be published.

**Funding**

This study was supported by the Medical Research Council grant G0600048 and Barbour Watson Grant.

**Conflict of interest**

None declared.

**References**

Aasmundstad TA, Haugen OA, Johannesen E, Hoe AL, Kvinsland S. Oestrogen receptor analysis: correlation between enzyme immunoassay and immunohistochemical methods. *J Clin Pathol* 1992; 45:125–129.

Bacci M, Capobianco A, Monno A, Cottone L, Di Puppo F, Camisa B, Mariani M, Brignole C, Ponponi M, Ferrari S et al. Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. *Am J Pathol* 2009; 175:547–556.

Baird DT, Cameron ST, Critchley HO, Drudy TA, Howe A, Jones RL, Lea RG, Kelly RW. Prostaglandins and menstruation. *Eur J Obstet Gynecol Reprod Biol* 1996; 70:15–17.

Bonatz G, Hansmann ML, Buchholz F, Mettler L, Radzun HJ, Senn K. Macrophage- and lymphocyte-subtypes in the endometrium during different phases of the ovarian cycle. *Int J Gynaecol Obstet* 1992; 37:29–32.

Brigstock DR. Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 kDa growth factor from airway smooth muscle interact with the extracellular matrix. *Am J Physiol Lung Cell Mol Physiol* 2006; 290:L153–L161.

Cao W, Mah K, Carroll RS, Slayden OD, Brenner RM. Progesterone withdrawal up-regulates fibronectin and integrins during menstruation and repair in the rhesus macaque endometrium. *Hum Reprod* 2007; 22:3233–3231.

Cicha I, Yilmaz A, Klein M, Raithel D, Brigstock DR, Daniel WG, Gopplott-Struebe M, Garchis CD. Connective tissue growth factor overexpression in complicated atherosclerotic plaques and induces mononuclear cell chemotaxis in vitro. *Arterioscler Thromb Vasc Biol* 2005; 25:1008–1013.

Critchley HO, Kelly RW, Brenner RM, Baird DT. The endocrinology of menstruation—a role for the immune system. *Clin Endocrinol (Oxf)* 2001; 55:701–710.

Critchley HO, Jones RL, Lea RG, Drudy TA, Kelly RW, Williams AR, Baird DT. Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. *J Clin Endocrinol Metab* 1999; 84:240–248.

Critchley HO, Osei J, Henderson TA, Boswell L, Sales KJ, Jabbour HN, Hirani N. Hypoxia-inducible factor-alpha expression in human endometrium and its regulation by prostaglandin E-series prostanoid receptor 2 (EP2). *Endocrinology* 2006; 147:744–753.

Eyster KM, Hansen KA, Winterton E, Klinkova O, Drapeau D, Mark-Kappeler CJ. Reciprocal communication between endometrial stromal cells and macrophages. *Reprod Sci* 2010; 17:809–822.

Fan X, Kriegl S, Kuo CJ, Wiegand S, Rabinovitch M, Druzin ML, Brenner RM, Giudice LC, Nayak NR. VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. *FASEB J* 2008; 22:3571–3580.

Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. *J Invest Dermatol* 1996; 107:404–411.

Gaide Chevrenay HP, Galant C, Lemoine P, Courtoy PJ, Marbaix E, Henriet P. Spatiotemporal coupling of focal extracellular matrix degradation and reconstruction in the menstrual human endometrium. *Endocrinology* 2009; 150:5094–5105.

Gaide Chevrenay HP, Lemoine P, Courtoy PJ, Marbaix E, Henriet P. Ovarian steroids, mitogen-activated protein kinases, and/or aspartic proteinases cooperate to control endometrial remodeling by regulating gene expression in the stroma and glands. *Endocrinology* 2010; 151:4515–4526.

Garry R, Hart R, Karthigas KA, Burke C. A re-appraisal of the morphological changes within the endometrium during menstruation: a hysteroscopic, histological and scanning electron microscopic study. *Hum Reprod* 2009; 24:1393–1401.

Gashaw I, Stiller S, Boing C, Kimming R, Winterhager E. Premenstrual regulation of the pro-angiogenic factor CYR61 in human endometrium. *Endocrinology* 2008; 149:2261–2269.

Harlow CR, Davidson L, Burns KH, Yan C, Matzuk MM, Hillier SG. FSH and TGF-beta superfamily members regulate granulosa cell connective tissue growth factor gene expression in vitro and in vivo. *Endocrinology* 2002; 143:3316–3325.

Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, Haase VH. Hypoxic induction of Ctgf is directly mediated by Hif-1. *Am J Physiol Renal Physiol* 2004; 287:F1223–F1232.

Hishikawa K, Nakaki T, Fuji T. Connective tissue growth factor induces apoptosis via caspase 3 in cultured human aortic smooth muscle cells. *Eur J Pharmacol* 2000; 392:19–22.

Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. *Mol Biol Cell* 1993; 4:637–645.
Ivkovic S, Yoon BS, Popoff SN, Safadi FF, Libuda DE, Stephenson RC, Daluiski A, Lyons KM. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003;130:2779–2791.

Kaitu’-u-Lino TJ, Morison NB, Salamonsen LA. Neutrophil depletion retards endometrial repair in a mouse model. Cell Tissue Res 2007;328:197–206.

Kamat BR, Isaacson PG. The immunocytochemical distribution of leukocytic subpopulations in human endometrium. Am J Pathol 1987;127:66–73.

Keightley MC, Brown P, Jabbour HN, Sales KJ. F-prostaglandin receptor regulates endothelial cell function via fibroblast growth factor-2. BMC Cell Biol 2010;11:8.

Kim JP, Zhang K, Kramer RH, Schall TJ, Woodley DT. Integrin receptors and RGD sequences in human keratinocyte migration: unique anti-migratory function of alpha 3 beta 1 epiligrin receptor. J Invest Dermatol 1992;98:764–770.

King AE, Critchley HO. Oestrogen and progesterone regulation of inflammatory processes in the human endometrium. J Steroid Biochem Mol Biol 2010;120:116–126.

Kreeva ML, Lam SC, Lau LF. Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphabeta3. J Biol Chem 1998;273:3090–3096.

Lau LF, Lam SC. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 1999;248:44–57.

Ludwig H, Spornitz UM. Microarchitecture of the human endometrium by scanning electron microscopy: menstrual desquamation and remodeling. Ann N Y Acad Sci 1991;622:28–46.

Markee JE. Menstruation in intraocular transplants in the rhesus monkey. Contrib Embryol 1940;28:219–308.

Maybin JA, Hirani N, Jabbour HN, Critchley HO. Novel roles for hypoxia and prostaglandin E2 in the regulation of IL-8 during endometrial repair. Am J Pathol 2011a;178:1245–1256.

Maybin JA, Hirani N, Brown P, Jabbour HN, Critchley HO. The regulation of vascular endothelial growth factor by hypoxia and prostaglandin F2(alpha) during human endometrial repair. J Clin Endocrinol Metab 2011b [Epub ahead of print].

Maybin JA, Battersby S, Hirani N, Nikitenko LL, Critchley HO, Jabbour HN. The expression and regulation of adrenomedullin in the human endometrium: a candidate for endometrial repair. Endocrinology 2011c;152:2845–2856.

Mile SA, Jabbour HN. Prostaglandin (PG) F(2alpha) receptor expression and signaling in human endometrium: role of PGF(2alpha) in epithelial cell proliferation. J Clin Endocrinol Metab 2003;88:1825–1832.

Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril 1950;1:3–25.

Oemar BS, Werner A, Garnier JM, Do DD, Godoy N, Nauck M, Marz W, Rupp J, Pech M, Luscher TF. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 1997;95:831–839.

Punyadeera C, Thijssen VL, Tchaikovski S, Kamps R, Delvoux B, Dunselman GA, de Goeij AF, Griffioen AW, Groothuis PG. Expression and regulation of vascular endothelial growth factor ligands and receptors during menstruation and post-menstrual repair of human endometrium. Mol Hum Reprod 2006;12:367–375.

Sales KJ, Maudsley S, Jabbour HN. Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3’,5’-adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signaling pathways. Mol Hum Reprod 2004;10:1533–1545.

Shimo T, Kubota S, Kondo S, Nakanishi T, Sasaki A, Mese H, Matsumura T, Takigawa M. Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line. Cancer Lett 2001;174:57–64.

Uzumcu M, Homsi MF, Ball DK, Coskun S, Jaroudi K, Hollanders JM, Briggstock DR. Localization of connective tissue growth factor in human uterine tissues. Mol Hum Reprod 2000;6:1093–1098.

Yu J, Prado GN, Schreiber B, Polgar P, Taylor L. Role of prostaglandin E(2) EP receptors and cAMP in the expression of connective tissue growth factor. Arch Biochem Biophys 2002;404:302–308.